UY24276A1 - Derivados del 4.9-etano-benzo(f)isoindol, como inhibidores de la farnesil transferasa, y las composiciones farmacéuticas que los contienen - Google Patents
Derivados del 4.9-etano-benzo(f)isoindol, como inhibidores de la farnesil transferasa, y las composiciones farmacéuticas que los contienenInfo
- Publication number
- UY24276A1 UY24276A1 UY24276A UY24276A UY24276A1 UY 24276 A1 UY24276 A1 UY 24276A1 UY 24276 A UY24276 A UY 24276A UY 24276 A UY24276 A UY 24276A UY 24276 A1 UY24276 A1 UY 24276A1
- Authority
- UY
- Uruguay
- Prior art keywords
- radical
- oxygen
- benzo
- sulfur
- formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/58—[b]- or [c]-condensed
- C07D209/72—4,7-Endo-alkylene-iso-indoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/572—Five-membered rings
- C07F9/5728—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Indole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente invención se refiere a productos de fórmula : 4,9-etano-benzo(f) isoindol, como inhibidores de farnesil transferasa, caracterizados por el compuesto de fórmula (I) donde R es un radical -(CH2)m-X1-(CH2)n-Z, donde X1 es un enlace simple o un átomo de oxígeno o de azufre, m es 0 ó 1 y n es 0,1,2, pudiendo los radicales metileno ser sustituídos por carboxi, cuya parte alquilo contiene 1 a 4 rtomos de carbono; Z es un radical carboxi, un radical COOR4, con R4 alquilo lineal o ramificado; R1 y R2 pueden ser idénticos o diferentes entre si y er H, halógeno, o radical alquilo con 1 a 4 átomos de carbono; R3 es H, o halógeno o un radical alquilo con 1 a 4 átomos de C; X es oxígeno, azufre , etileno,etc; Y es oxígeno o azufre. Estos nuevos productos de fórmula (I) son inhibidores de la farnesil transferasa y presentan notables propiedades antitumorales y antileucémicas. De acuerdo a la invención los productos de fórmula general (I) donde Y es oxígeno o azufre y X es NH, puede obtenerse haciendo reacionar un isocianato o un isotiocianato de fórmula general (IV)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9508296A FR2736641B1 (fr) | 1995-07-10 | 1995-07-10 | Nouveaux inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY24276A1 true UY24276A1 (es) | 2001-10-25 |
Family
ID=9480830
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY24276A UY24276A1 (es) | 1995-07-10 | 1996-07-08 | Derivados del 4.9-etano-benzo(f)isoindol, como inhibidores de la farnesil transferasa, y las composiciones farmacéuticas que los contienen |
Country Status (32)
| Country | Link |
|---|---|
| US (1) | US5936097A (es) |
| EP (1) | EP0839133B1 (es) |
| JP (1) | JPH11511123A (es) |
| KR (1) | KR19990028856A (es) |
| CN (1) | CN1096448C (es) |
| AR (1) | AR003143A1 (es) |
| AT (1) | ATE185341T1 (es) |
| AU (1) | AU712194B2 (es) |
| BR (1) | BR9609440A (es) |
| CA (1) | CA2224414A1 (es) |
| CO (1) | CO4700457A1 (es) |
| CZ (1) | CZ291620B6 (es) |
| DE (1) | DE69604588T2 (es) |
| DK (1) | DK0839133T3 (es) |
| EA (1) | EA000797B1 (es) |
| ES (1) | ES2139373T3 (es) |
| FR (1) | FR2736641B1 (es) |
| GR (1) | GR3031409T3 (es) |
| IL (1) | IL122812A (es) |
| MA (1) | MA23929A1 (es) |
| MX (1) | MX9800262A (es) |
| MY (1) | MY114792A (es) |
| NO (1) | NO309565B1 (es) |
| NZ (1) | NZ313211A (es) |
| PE (1) | PE11898A1 (es) |
| PL (1) | PL324430A1 (es) |
| SK (1) | SK282250B6 (es) |
| TN (1) | TNSN96098A1 (es) |
| TW (1) | TW438792B (es) |
| UY (1) | UY24276A1 (es) |
| WO (1) | WO1997003050A1 (es) |
| ZA (1) | ZA965868B (es) |
Families Citing this family (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6013662A (en) * | 1996-12-30 | 2000-01-11 | Rhone-Poulenc Rorer S.A. | Farnesyl transferase inhibitors, their preparation, the pharmaceutical compositions which contain them and their use in the preparation of medicaments |
| FR2757855B1 (fr) * | 1996-12-30 | 1999-01-29 | Rhone Poulenc Rorer Sa | Nouveaux inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent |
| US6124465A (en) * | 1997-11-25 | 2000-09-26 | Rhone-Poulenc S.A. | Farnesyl transferase inhibitors, their preparation, the pharmaceutical compositions which contain them and their use in the preparation of medicaments |
| AU1767599A (en) * | 1997-12-23 | 1999-07-19 | Aventis Pharma S.A. | Novel farnesyl transferase inhibitors, preparation, pharmaceutical compositions containing them and use for preparing medicines |
| FR2772764B1 (fr) * | 1997-12-23 | 2000-01-14 | Rhone Poulenc Rorer Sa | Nouveaux inhibiteurs de farnesyle transferase, leur preparation, les compositions pharmaceutiques qui les contiennent et leur utilisation pour la preparation de medicaments |
| FR2787327B1 (fr) * | 1998-12-21 | 2003-01-17 | Aventis Pharma Sa | Compositions contenant des inhibiteurs de farnesyle transferase |
| FR2796641B1 (fr) | 1999-07-22 | 2001-09-21 | Aventis Pharma Sa | Nouveau procede de preparation de composes benzoperhydroisoindole |
| US20020177575A1 (en) * | 2001-05-04 | 2002-11-28 | Ward Wakeland | Identification of farnesyl-protein transferase as a target for systemic lupus erythematosus therapies |
| ATE550019T1 (de) | 2005-05-17 | 2012-04-15 | Merck Sharp & Dohme | Cis-4-ä(4-chlorophenyl)sulfonylü-4-(2,5- difluorophenyl)cyclohexanepropansäure zur behandlug von krebs |
| GB0603041D0 (en) | 2006-02-15 | 2006-03-29 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| EP2698157B1 (en) | 2006-09-22 | 2015-05-20 | Merck Sharp & Dohme Corp. | Method of treatment using fatty acid synthesis inhibitors |
| US20110218176A1 (en) | 2006-11-01 | 2011-09-08 | Barbara Brooke Jennings-Spring | Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development |
| EP2109608B1 (en) | 2007-01-10 | 2011-03-23 | Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. | Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors |
| MX2009009304A (es) | 2007-03-01 | 2009-11-18 | Novartis Ag | Inhibidores de cinasa pim y metodos para su uso. |
| CN101754965B (zh) | 2007-05-21 | 2014-03-19 | 诺华股份有限公司 | Csf-1r抑制剂、组合物及使用方法 |
| US8389553B2 (en) | 2007-06-27 | 2013-03-05 | Merck Sharp & Dohme Corp. | 4-carboxybenzylamino derivatives as histone deacetylase inhibitors |
| US7932036B1 (en) | 2008-03-12 | 2011-04-26 | Veridex, Llc | Methods of determining acute myeloid leukemia response to treatment with farnesyltransferase |
| EP2413932A4 (en) | 2009-04-01 | 2012-09-19 | Merck Sharp & Dohme | INHIBITORS OF AKT ACTIVITY |
| US8765747B2 (en) | 2009-06-12 | 2014-07-01 | Dana-Farber Cancer Institute, Inc. | Fused 2-aminothiazole compounds |
| EP2488028B1 (en) | 2009-10-14 | 2020-08-19 | Merck Sharp & Dohme Corp. | Substituted piperidines that increase p53 activity and the uses thereof |
| EP2519517B1 (en) | 2009-12-29 | 2015-03-25 | Dana-Farber Cancer Institute, Inc. | Type ii raf kinase inhibitors |
| BR112012023021A2 (pt) | 2010-03-16 | 2016-05-31 | Dana Farber Cancer Inst Inc | compostos de indazol e seus usos |
| WO2011163330A1 (en) | 2010-06-24 | 2011-12-29 | Merck Sharp & Dohme Corp. | Novel heterocyclic compounds as erk inhibitors |
| AU2011282614B2 (en) | 2010-07-28 | 2015-11-26 | Janssen Pharmaceutica Nv | Methods of determining Acute Myeloid Leukemia response to treatment with farnesyltransferase inhibitors |
| CN103068980B (zh) | 2010-08-02 | 2017-04-05 | 瑟纳治疗公司 | 使用短干扰核酸（siNA）的RNA干扰介导的联蛋白（钙粘蛋白关联蛋白质），β1（CTNNB1）基因表达的抑制 |
| KR102072631B1 (ko) | 2010-08-17 | 2020-02-03 | 시르나 쎄러퓨틱스 인코퍼레이티드 | 짧은 간섭 핵산 （ｓｉＮＡ）을 사용한 Ｂ형 간염 바이러스 （ＨＢＶ） 유전자 발현의 ＲＮＡ 간섭 매개 억제 |
| US8883801B2 (en) | 2010-08-23 | 2014-11-11 | Merck Sharp & Dohme Corp. | Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors |
| WO2012030685A2 (en) | 2010-09-01 | 2012-03-08 | Schering Corporation | Indazole derivatives useful as erk inhibitors |
| US9242981B2 (en) | 2010-09-16 | 2016-01-26 | Merck Sharp & Dohme Corp. | Fused pyrazole derivatives as novel ERK inhibitors |
| EP3766975A1 (en) | 2010-10-29 | 2021-01-20 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina) |
| WO2012087772A1 (en) | 2010-12-21 | 2012-06-28 | Schering Corporation | Indazole derivatives useful as erk inhibitors |
| US20140046059A1 (en) | 2011-04-21 | 2014-02-13 | Piramal Enterprises Limited | Process for the preparation of morpholino sulfonyl indole derivatives |
| US9023865B2 (en) | 2011-10-27 | 2015-05-05 | Merck Sharp & Dohme Corp. | Compounds that are ERK inhibitors |
| EP2822935B1 (en) | 2011-11-17 | 2019-05-15 | Dana-Farber Cancer Institute, Inc. | Inhibitors of c-jun-n-terminal kinase (jnk) |
| US20150299696A1 (en) | 2012-05-02 | 2015-10-22 | Sirna Therapeutics, Inc. | SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS |
| WO2014052563A2 (en) | 2012-09-28 | 2014-04-03 | Merck Sharp & Dohme Corp. | Novel compounds that are erk inhibitors |
| EP2909194A1 (en) | 2012-10-18 | 2015-08-26 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
| WO2014063061A1 (en) | 2012-10-19 | 2014-04-24 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged small molecules as inducers of protein degradation |
| US10000483B2 (en) | 2012-10-19 | 2018-06-19 | Dana-Farber Cancer Institute, Inc. | Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof |
| ES2651347T3 (es) | 2012-11-28 | 2018-01-25 | Merck Sharp & Dohme Corp. | Composiciones y métodos para el tratamiento del cáncer |
| CA2895504A1 (en) | 2012-12-20 | 2014-06-26 | Merck Sharp & Dohme Corp. | Substituted imidazopyridines as hdm2 inhibitors |
| US9540377B2 (en) | 2013-01-30 | 2017-01-10 | Merck Sharp & Dohme Corp. | 2,6,7,8 substituted purines as HDM2 inhibitors |
| WO2015034925A1 (en) | 2013-09-03 | 2015-03-12 | Moderna Therapeutics, Inc. | Circular polynucleotides |
| US20160264551A1 (en) | 2013-10-18 | 2016-09-15 | Syros Pharmaceuticals, Inc. | Heteroaromatic compounds useful for the treatment of prolferative diseases |
| EP3057956B1 (en) | 2013-10-18 | 2021-05-05 | Dana-Farber Cancer Institute, Inc. | Polycyclic inhibitors of cyclin-dependent kinase 7 (cdk7) |
| WO2015164604A1 (en) | 2014-04-23 | 2015-10-29 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged janus kinase inhibitors and uses thereof |
| WO2015164614A1 (en) | 2014-04-23 | 2015-10-29 | Dana-Farber Cancer Institute, Inc. | Janus kinase inhibitors and uses thereof |
| JO3589B1 (ar) | 2014-08-06 | 2020-07-05 | Novartis Ag | مثبطات كيناز البروتين c وطرق استخداماتها |
| WO2016105528A2 (en) | 2014-12-23 | 2016-06-30 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
| US10550121B2 (en) | 2015-03-27 | 2020-02-04 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinases |
| WO2016201370A1 (en) | 2015-06-12 | 2016-12-15 | Dana-Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
| PT3277842T (pt) | 2015-08-17 | 2019-09-05 | Kura Oncology Inc | Métodos de tratamento de doentes com cancro usando inibidores da farnesiltransferase |
| EP4019515A1 (en) | 2015-09-09 | 2022-06-29 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinases |
| JOP20190055A1 (ar) | 2016-09-26 | 2019-03-24 | Merck Sharp & Dohme | أجسام مضادة ضد cd27 |
| EP3838275A1 (en) | 2016-11-03 | 2021-06-23 | Kura Oncology, Inc. | Farnesyltransferase inhibitors for use in methods of treating cancer |
| US10851164B2 (en) | 2017-04-13 | 2020-12-01 | Aduro Biotech Holdings, Europe B.V. | Anti-SIRPα antibodies |
| US10947234B2 (en) | 2017-11-08 | 2021-03-16 | Merck Sharp & Dohme Corp. | PRMT5 inhibitors |
| WO2019113269A1 (en) | 2017-12-08 | 2019-06-13 | Kura Oncology, Inc. | Methods of treating cancer patients with farnesyltransferase inhibitors |
| WO2019148412A1 (en) | 2018-02-01 | 2019-08-08 | Merck Sharp & Dohme Corp. | Anti-pd-1/lag3 bispecific antibodies |
| WO2020033282A1 (en) | 2018-08-07 | 2020-02-13 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
| WO2020033284A1 (en) | 2018-08-07 | 2020-02-13 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
| TW202108170A (zh) | 2019-03-15 | 2021-03-01 | 美商庫拉腫瘤技術股份有限公司 | 以法呢基轉移酶(farnesyltransferase)抑制劑治療癌症患者之方法 |
| EP4303246A1 (de) | 2022-07-04 | 2024-01-10 | Covestro Deutschland AG | Polyisocyanatgemisch |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2492372A1 (fr) * | 1980-10-21 | 1982-04-23 | Cird | Dihydroxy-1,8 anthrones-9 substituees en position 10 et leur utilisation en medecine humaine ou veterinaire et en cosmetique |
| JP3597863B2 (ja) * | 1993-11-05 | 2004-12-08 | ワーナー−ランバート・コンパニー | タンパク質：ファルネシルトランスフェラーゼの置換されたジ‐およびトリペプチド阻害剤 |
-
1995
- 1995-07-10 FR FR9508296A patent/FR2736641B1/fr not_active Expired - Fee Related
-
1996
- 1996-07-03 MA MA24302A patent/MA23929A1/fr unknown
- 1996-07-04 PE PE1996000510A patent/PE11898A1/es not_active Application Discontinuation
- 1996-07-05 TW TW085108158A patent/TW438792B/zh not_active IP Right Cessation
- 1996-07-08 PL PL96324430A patent/PL324430A1/xx unknown
- 1996-07-08 CZ CZ199854A patent/CZ291620B6/cs not_active IP Right Cessation
- 1996-07-08 KR KR1019980700157A patent/KR19990028856A/ko not_active Application Discontinuation
- 1996-07-08 CA CA002224414A patent/CA2224414A1/fr not_active Abandoned
- 1996-07-08 UY UY24276A patent/UY24276A1/es not_active IP Right Cessation
- 1996-07-08 BR BR9609440A patent/BR9609440A/pt not_active Application Discontinuation
- 1996-07-08 EP EP96924952A patent/EP0839133B1/fr not_active Expired - Lifetime
- 1996-07-08 NZ NZ313211A patent/NZ313211A/xx unknown
- 1996-07-08 SK SK26-98A patent/SK282250B6/sk unknown
- 1996-07-08 JP JP9505557A patent/JPH11511123A/ja active Pending
- 1996-07-08 WO PCT/FR1996/001062 patent/WO1997003050A1/fr not_active Application Discontinuation
- 1996-07-08 DE DE69604588T patent/DE69604588T2/de not_active Expired - Fee Related
- 1996-07-08 AU AU65224/96A patent/AU712194B2/en not_active Ceased
- 1996-07-08 DK DK96924952T patent/DK0839133T3/da active
- 1996-07-08 MX MX9800262A patent/MX9800262A/es not_active IP Right Cessation
- 1996-07-08 US US08/981,840 patent/US5936097A/en not_active Expired - Fee Related
- 1996-07-08 EA EA199800118A patent/EA000797B1/ru not_active IP Right Cessation
- 1996-07-08 AT AT96924952T patent/ATE185341T1/de not_active IP Right Cessation
- 1996-07-08 ES ES96924952T patent/ES2139373T3/es not_active Expired - Lifetime
- 1996-07-08 IL IL12281296A patent/IL122812A/en not_active IP Right Cessation
- 1996-07-08 CN CN96195415A patent/CN1096448C/zh not_active Expired - Fee Related
- 1996-07-09 TN TNTNSN96098A patent/TNSN96098A1/fr unknown
- 1996-07-10 ZA ZA965868A patent/ZA965868B/xx unknown
- 1996-07-10 MY MYPI96002848A patent/MY114792A/en unknown
- 1996-07-10 AR ARP960103511A patent/AR003143A1/es unknown
- 1996-07-10 CO CO96036152A patent/CO4700457A1/es unknown
-
1998
- 1998-01-09 NO NO980094A patent/NO309565B1/no unknown
-
1999
- 1999-10-07 GR GR990402001T patent/GR3031409T3/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY24276A1 (es) | Derivados del 4.9-etano-benzo(f)isoindol, como inhibidores de la farnesil transferasa, y las composiciones farmacéuticas que los contienen | |
| BR8904702A (pt) | Pirimidinas substituidas com arilenodiaminas,uma composicao resistente a degradacao,um artigo elastomerico protegido contra degradacao e um processo de fabricacao de pirimidinas substituidas | |
| ATE244273T1 (de) | Schwefelenthaltende additionsverbindungen von polythiolen und norbornenderivaten, verfahren zu ihrer herstellung und ihrer anwendung zur gewinnung von mittels radikalbildung vernetzen produkten | |
| MX165512B (es) | Aditivo de carbamato para composicion lubricante | |
| ES2101513T3 (es) | Nuevos taxoides, su preparacion y las composiciones farmaceuticas que les contienen. | |
| ATE187471T1 (de) | Selbstverlöschende polymerzusammensetzungen | |
| ATE86638T1 (de) | Verfahren zur herstellung von thioether-funktion enthaltendem polybuten. | |
| HUT47136A (en) | Process for producing cyclic peptides with anticoagulant effect | |
| ES465881A1 (es) | Procedimiento para la preparacion de composiciones polimeri-cas autoextinguentes. | |
| ES2137626T3 (es) | Procedimiento para la preparacion de derivados de ciclopentadienilo. | |
| DE69129057D1 (de) | Selbstverlöschende polymere Zusammensetzungen | |
| NO894349D0 (no) | Tienopyridin-type mevalonolaktoner. | |
| ES8304177A1 (es) | Un procedimiento, para la reticulacion de composiciones plastomeras, elastomeras naturales o sinteticas y resinas termo-endurecibles. | |
| GB1353532A (en) | Triazine compounds and process for crosslinking rubber | |
| UA40573C2 (uk) | Похідні 2-ціано-3-гідроксипропенаміду, спосіб їх одержання (варіанти) та фармацевтична композиція на їх основі | |
| DE69318091T2 (de) | Verfahren zur Vulkanisation, von Kautschuk ohne Nitrosaminbildung | |
| NO913769L (no) | Forbindelse, fremstilling og anvendelse. | |
| FR2632521B1 (fr) | Nouveaux derives de la phenothiazine, leur preparation et les compositions pharmaceutiques qui les contiennent | |
| ES2051955T3 (es) | Compuestos azaalifaticos ciclicos con funcion nitroxi, procedimiento para su produccion y medicamentos que contienen estos compuestos. | |
| GR1001309B (el) | Μεθοδος παρασκευης παραγωγου ενωσεως της διχλωροανιλινης. | |
| ES2172033T3 (es) | Inhibidores de farnesil transferasa. | |
| ES378034A1 (es) | Un metodo para la produccion de un compuesto herbicida. | |
| TW360627B (en) | Cyclopentadienyl derivatives and process for the preparation | |
| GB959997A (en) | Formamido-chloroformamidines | |
| Cain et al. | 616. Oxidation of organic sulphides. Part XIV. The antioxidant effect of organic sulphur compounds structurally related to crosslinks in natural rubber vulcanisates |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| VENC | Patent expired |
Effective date: 20160708 |